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Background: Stromal cell-derived factor-1 (SDF-1) (CXC chemokine ligand-12)/CXC chemokine receptor 4 (CXCR4)
is involved in the carcinogenesis of human gastric cancer, where it stimulates angiogenesis and favors metastasis of
tumor cells to distant organs. In addition, resistin is suggested to be an important link between obesity and the
development of gastric cancer. Resistin has identified as an important player in inflammatory responses, and emerged as
a mediator in inflammation-associated cancer. A limited number of studies have investigated the association of resistin
and SDF-1 with gastric cancer. Herein, we investigated the molecular mechanisms by which resistin influences the
expression of SDF-1 in gastric carcinoma cells.
Results: Human gastric cancer cell lines were exposed to doses of resistin; SDF-1 expression and secretion levels were
then determined. Real-time polymerase chain reaction and western blotting analyses were performed to clarify molecular
changes. Inhibition of Toll-like receptor 4 (TLR4) by a competitive antagonist inhibited resistin-induced SDF-1 expression.
Pharmacological inhibitors and small interfering RNA (siRNA) demonstrated that activation of the p38 mitogen-activated
protein kinase (MAPK) pathway is critical for resistin-induced SDF-1 expression mediated by TLR4. The promoter activity
and transcription factor enzyme-linked immunosorbent assay revealed that resistin induced expression of SDF-1 mediated
by NF-κB in gastric cancer cells. Inhibition of p38 MARK activation blocked the SDF-1-induced expression and the SDF-1
promoter activity in the cancer gastric cells. Chromatin immunoprecipitation assay revealed that inhibition of p38 MARK
activation also blocked the resistin-increased NF-κB-DNA-binding activity.
Conclusions: Resistin-induced SDF-1 upregulation by activation of TLR4, p38 MARK and NF-κB may explain a new role of
resistin in the link of obesity and gastric cancer.
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Gastric cancer ranks as the fourth most frequent of ma-
lignant tumors [1]. Although it is the second or third
most frequent cause of cancer death worldwide [2], its
etiology is not well understood. The disease is often the
result of long-term interactions of many factors relating
to individual habits, diet, environment, and genetics, as
well as chronic gastritis, gastric polyps, gastric dysplasia,
post-surgery gastric remnants, and long-term infection
by Helicobacter pylori [3]. H. pylori is recognized as a
causative factor of chronic gastritis, gastroduodenal ul-
cers, gastric cancer, and mucosa-associated lymphatic
tissue lymphoma. In previous study, chronic gastritis re-
lated human diseases, including gastroduodenal ulcers,
gastric cancer, and mucosa-associated lymphatic tissue
lymphoma, were found to result from an excessive for-
mation of epithelial cells or gastric mucin injury and
inflammation caused by chronic H. pylori infection [4].
Several studies have indicated that the typical LPSs rec-
ognized by the Toll-like receptor 4 (TLR4) complex
expressed on host cells, contributing to activation of
the p38 mitogen-activated protein kinase (MARK)
pathway [5,6].
Obesity is a risk factor for gastric cancer mainly be-
cause obesity enhances the incidence of gastroesopha-
geal reflux, which may damage the mucosa around the
gastric cardia, resulting in an increased likelihood of
cancer. Obesity is defined as a very high ratio of body fat
to other tissue [7]. Too much body fat has a significant
impact on health, particularly in terms of insulin resist-
ance. The proteins secreted by the fat tissues play a very
important role in regulating metabolism [8]. The regula-
tion of resistin in carbohydrate metabolism is considered
to be associated with insulin resistance. Resistin is cap-
able of regulating the insulin-stimulated metabolism of
carbohydrates in many insulin target organs [9]. Since
the discovery of resistin, most studies have focused on
the relationship of resistin to obesity and diabetes. An
increasing number of studies have focused on the role of
resistin in cancer development, and the impact of resis-
tin on inflammation is the focus of several current
academic studies [10,11]. These studies have found that
resistin is negatively correlated with high density lipopro-
teins in diabetic patients; however, resistin is positively
correlated with C-reactive protein (CRP), an indicator of
inflammation [12]. This association indicates that higher
levels of the resistin may be related to inflammatory re-
sponses. In addition, studies have found that adipose tissue
is not the exclusive source of resistin; large amounts of
resistin and resistin-like molecules are also found in non-
adipose tissues under inflammation [13]. Inflammatory
response can release interleukin (IL)-6, IL-8, IL-1β, and
tumor necrosis factor alpha (TNFα) through the NF-κB
pathway [11]. Thus far, no study has investigated theassociation of resistin and any known receptor to activate
downstream MAPK kinase that further activate nuclear
factor-κB (NF-κB p50/p65) in human gastric cancer.
Chemoattractant proteins are a group of small pro-
teins of molecular weight ranging from 8 to 12 kDa that
can be induced by inflammatory substances to release
into the extracellular environment. More than 40 types
of human cell chemoattractant proteins have been iden-
tified [14]. Chemoattractant proteins have a number of
functions such as inducing the movement, growth, and
differentiation of white blood cells. These inflammatory
responses are closely related to gastric cancer [15]. One
of the causative factors of inflammatory responses is the
production and induction of chemoattractant proteins.
Previous studies have found that the stromal cell-derived
factor-1 (SDF-1) can regulate cancerous cell movement
and blood vessel regeneration via its specific receptors
CXCR4 and CXCR7 [16]. Gastric inflammation is an in-
tegral step in gastric cancer development; therefore, fac-
tors inducing and regulating responses to inflammation
may play a key role in gastric cancer prognoses [17].
From this viewpoint, because chemokines have certain
roles in microbial immune and inflammation responses,
the resistin-induced secretion of SDF-1 may be corre-
lated to the control of gastric cancer.
Gastric cancer can be correlated with obesity. Re-
searchers have pointed out that resistin is the blood
biological indicator of gastric cancer and is related to
patient prognosis [18]. Moreover, SDF-1 acts in can-
cerous cells as a growth and survival factor; however,
the implication of resistin stimulation by the chemo-
attractant SDF-1 has not been studied. In the present
study, we investigated whether resistin stimulates the
expression of SDF-1 by activating the p38 MAPK intra-
cellular signaling cascades and the transcription factors
NF-κB and p50. Our findings provide evidence of the
molecular mechanisms of SDF-1 expression and its
secretion by resistin via a TLR4-dependent pathway in
gastric cancer cells.
Methods
Chemical reagents and antibodies
All culture materials were purchased from Gibco (Grand
Island, NY). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), PD98059 (MEK1 inhibitor),
SP600125 (JNK inhibitor), SB203580 (p38 inhibitor), SN50,
and PDTC (pyrrolidinedithiocarbamate ammonium) were
purchased from Sigma (St. Louis, MO). Mouse monoclonal
antibodies against p38 MARK (9 F12) and phospho-p38
MARK (D-8) were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Human CXCL12/SDF-1 enzyme-
linked immunosorbent assay (ELISA) kit was obtained from
Cell Sciences (Canton, MA). ERK siRNA (ordering number:
s11137 and s11143), JNK siRNA (ordering number: 1452
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siRNA (ordering number: 5121), p65 siRNA (ordering
number: s11916), and control siRNA (scrambled nega-
tive control containing random DNA sequences) were
purchased from Invitrogen (Carlsbad, CA). TLR4 siRNA
was purchased from Sigma-Proligo (Singapore). The bacter-
ial lipopolysaccharide from Rhodobacter sphaeroides (LPS-
RS, TLR4 antagonist) was obtained from Invivogen (San
Diego, CA).
Cell culture
The gastric carcinoma cell line TSGH 9201 and AGS
cells was purchased from the Bioresources Collection
and Research Center (BCRC) of the Food Industry Re-
search and Development Institute (Hsinchu, Taiwan). Cells
were maintained in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin in
a CO2 incubator at 37°C.
Real-time quantitative PCR
Real-time PCR was performed using an ABI Prism
7900HT with the FastStart DNA SYBR Green I kit
(Roche Diagnostics GMbH, Mannheim, Germany). The
designed primers in this study were SDF-1 forward pri-
mer, 5'- ATTCTCAACACTCCAAACTGTGC-3'; SDF-1
reverse primer, 5'- ACTTTAGCTTCGGGTCAATGC-3';
18S rRNA forward primer, 5'-CGGCG ACGAC CCAT
T CGAAC-3'; and 18S rRNA reverse primer, 5'-GAATC
GAACC CTGAT TCCCC GTC-3'. Quantification was
performed using the 2−ΔΔCt method [19]. All samples were
measured in duplicate. The average value of the duplicates
was used as the quantitative value.
ELISA
CXCL12/SDF-1 expression on the cancer cell surface
was measured by ELISA as previously described [19].
Release of SDF-1 into culture media was analyzed using
commercially available ELISA kit purchased from Cell
Sciences (Canton, MA). The assays and data calcula-
tions were performed according to the manufacturer’s
instructions.
Preparation of total cell extracts and immunoblot
analyses
TSGH 9201 cells were lysed with a buffer containing 1%
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), and a protease inhibitor mixture (phenyl-
methylsulfonyl fluoride, aprotinin, and sodium orthova-
nadate). The total cell lysate (50 μg of protein) was
separated by SDS-polyacrylamide gel electrophoresis
(PAGE) (12% running, 4% stacking) and analyzed by
using the designated antibodies and the Western-Light
chemiluminescent detection system (Bio-Rad, Hercules,
CA), as previously described [20].DNA plasmid, siRNA, transfection, and luciferase assay
Human SDF-1 promoter constructs containing −1010/+
30, −630/+30, −430/+122, −214/+30, −121/+30, and −20/+
30 of SDF-1 5'-flanking DNA linked to the firefly luciferase
reporter gene of plasmid pGL4 (Promega, Madison, WI)
were used as previously reported [21]. DNA plasmids
at a concentration of 1 mg/ml were transfected into
TSGH 9201 cells by Lipofectamine (Gibco, Carlsbad,
CA). The pSV-β-galactosidase plasmid was cotrans-
fected to normalize the transfection efficiency. For
siRNA transfection, TSGH 9201 cells were transfected
with the designated siRNA using an RNAiMAX trans-
fection kit (Invitrogen, Carlsbad, CA) [19]. The effect-
iveness of the silencing was validated: ERK-, JNK-, p38
MARK-, p65-, and p50-specific siRNAs (compared
with control siRNA) caused at least 80% reduction in
the protein expression of ERK, JNK, p38 MARK, p65,
and p50, respectively. The cells were transfected with
the specific TLR4 siRNA (CGAUGAUAUUAUUGACUUA
[dT]; [dT]UAAGUCAAUAAUAUCAUGG[dT][dT]).
NFκB p50 transcription factor assay (TF ELISA assay)
Nuclear extracts of cells were prepared by nuclear pro-
tein extract kit (Panomics, Redwood City, CA). Equal
amounts of nuclear proteins were used for quantitative
measurements of NF-κB p50 activation using commer-
cially available ELISA kit (Panomics, Redwood City, CA)
that measure p50 DNA-binding activities [19].
Chromatin immunoprecipitation assay (ChIP)
The ChIP assay was carried out as previously described
and ChIP assay kit used was from Upstate Biotechnology
(Lake Placid, NY) [19]. Cells were fixed with 1% formal-
dehyde, washed, then harvested in SDS lysis buffer. After
sonication, lysates containing soluble chromatin were
immunoprecipitated using 2 μg of antibody against p50.
DNA was purified with a PCR Purification Kit (QIA-
GEN, Venlo, The Netherlands). The resulting DNA was
used for PCR analysis, and the amplified DNA fragments
were visualized on an agarose gel. PCR was performed
with the following primers that amplify the parts of the
human SDF-1 promoter that contain the p50 binding sites
from −669 ~ −569: 5'- GTTTCCACAGGCGAATGG -3'
and 5'- GGACCTCACAGCCTCAAGTC -3'.
Statistical analysis
The experiments were performed in triplicate independ-
ent experiments, and data were presented as three re-
peats from one independent experiment. Data were
reported as the mean ± standard deviation or standard
error of the mean and evaluated by one-way analysis of
variance. SPSS version 16.0 (SPSS, Inc., Chicago, IL) was
used for all statistical analyses. Significant differences
were established at P < 0.05.
Figure 1 Induction of SDF-1 expression in human gastric carcinoma cell line TSGH 9201 and AGS cells by resistin stimulation. TSGH 9201 and
AGS cells were treated with vehicle and resistin treatment. RNA samples were isolated at the indicated time periods or doses. All bar graphs represent
folds of control cells (CL) and normalized to 18S rRNA by real-time PCR analysis (A, C). Human SDF-1 protein secretion was determined by ELISA analyses
(B, D). Cells were stimulated with 25 ng/mL resistin for the times indicated (A, B), or induced at various doses for 4 h (C) or 6 h (D). RNA levels were
quantified with the control being set at 100%. The experiments were performed in triplicate, and data are presented as means ± SD. The symbol *indicates









Figure 2 p38 MAPK pathway is required for resistin-stimulated SDF-1 expression. (A) TSGH 9201 cells were incubated with various concentrations
of the specific MEK1 inhibitor PD98059 (PD, 10 μM), the c-Jun N-Terminal Kinase (JNK/SAP Kinase) Inhibitors SP600125 (SP, 10 μM), or the p38 Inhibitor SB
203580 (SB, 10 μM) for 1 h, transfected with control siRNA (si-CL), control pcDNA3 vector (vec), or a specific siRNA of si-ERK, si-JNK, or si-p38. Next, the cells
were treated with 25 ng/mL resistin for 4 h (B) or 6 h (C). (B) All bar graphs represent folds of CL group and normalized to 18S rRNA. (C) Human SDF-1
secretion was determined by ELISA. The results are shown as mean ± SEM. *P< 0.05 versus CL. #P< 0.05 versus vehicle control (DMSO) or control siRNA
(si-CL) with resistin stimulation. (D) Total cell lysates of cells treated with or without resistin for the indicated time were extracted, and the phosphorylated
proteins of p38 MAPK, and p38 MARK were immunodetected as described in “Materials and Methods”. Protein levels were quantified by densitometric
analysis, with the control being set at 100%.
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Figure 3 Effect of the TLR4 antagonist in blocking resistin-induced expression of SDF-1 and p38 MAPK. (A) TSGH 9201 cells were kept as control
(CL) or stimulated with 25 ng/mL resistin. Cells were pretreated with or without 1 or 2 mg/ml LPS-RS for 1 h and then stimulated with 25 ng/mL resistin
for 4 h. SDF-1 mRNA levels were determined through real-time PCR in TSGH cells and normalized to 18S rRNA. (B) SDF-1-1010-Luc activity were
determined in TSGH cells with or without 1 or 2 mg/ml LPS-RS for 1 h. (C) TSGH cells were kept as CL or stimulated with resistin for 30 min, and the
phosphorylation of p38 was determined by western blotting. All bar graphs represent folds of CL cells. *P< 0.05 versus CL. #P< 0.05 versus vehicle control
(DMSO). (D) TSGH 9201 cells were transfected with control siRNA (si-CL) or a specific siRNA of si-TLR4 and the cells were treated with 25 ng/mL resistin for
30 min and 6 h, and then the phosphorylation of p38 and TLR4 were determined by western blotting. Human SDF-1 secretion was determined by ELISA.
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Effect of resistin on expression of SDF-1 in gastric
carcinoma TSGH 9201 and AGS cells
To determine whether SDF-1 is induced by resistin, we ex-
posed the human gastric cancer cell lines TSGH 9201 and
AGS to a range of resistin doses and performed experimen-
tal assays. Cells were exposed to a 25 ng/mL dose of resistin
for the indicated times. The changes in SDF-1 mRNA ex-
pression were analyzed by real-time PCR; SDF-1 secretion
in conditioned media was detected by ELISA. The SDF-1
mRNA reached its highest level at 4 h of resistin stimula-
tion (Figure 1A). The secretion of SDF-1 protein began to
increase after resistin treatment and reached its highest
level at 6 h (Figure 1B). In addition, the resistin-induced
SDF-1 mRNA expression and protein secretion in TSGH
9201 cells was dose dependent (Figure 1C-D). The results
demonstrate that resistin significantly induced gene expres-
sion. Based on our results, it is possible that in gastric car-
cinoma cell, resistin induced pathway-related proteins may
be studied as potential markers in terms of the prediction
of response to treatment or prognosis. Further investiga-
tion, we used TSGH 9201 Cell to evaluate the effect of
resistin on other pro-tumoral CXC chemokines gene ex-
pression. Our data demonstrate that resistin significantly
induced-related gene expression, such as GRO, ENA78,
GCP-2 or IL-8 (Additional file 1: Figure S1).Resistin-induced SDF-1 expression in gastric cancer is
mediated by p38 MAPK
To clarify the events of resistin-induced SDF-1 expres-
sion, we analyzed specific MAPK siRNAs to determine
the signaling pathways associated with resistin-induced
SDF-1 expression in TSGH 9201 cells (Figure 1A). As
shown in Figure 2B and C, the mRNA level and secre-
tion of SDF-1 were increased by the resistin stimulation,
and they were significantly inhibited by SB203580, but
not by PD98059 or SP600125. To further confirm the in-
volvement of p38 MAPK, but not ERK and JNK, in the
modulation of the SDF-1 expression by resistin induc-
tion, we examined the effects of specific MAPK siRNAs
of these signaling pathways on resistin-induced SDF-1
expression in TSGH 9201 cells (Figure 2A). The resistin-
induced SDF-1 mRNA expression (Figure 2B) and SDF-
1 secretion (Figure 2C) were inhibited by transfection
with p38- siRNA, but not by transfection with ERK-,
JNK-, and control siRNAs (100 mmol/ml for each).
These data suggest that the p38 MAPK pathway is in-
volved in regulating the resistin-induced SDF-1 expres-
sion in gastric cancer cells. To determine the effect of
resistin on the activation of the kinase signaling pathway,
we assessed whole cell lysates from resistin-treated
TSGH 9201 cells by Western blotting analysis using
antibodies against activated Phospho-p38 MAPK and
Figure 4 Effect of NFκB in resistin-induced SDF-1 mRNA expression and promoter activity. (A) SDF-1 mRNA and (B) SDF-1-1010-Luc activity were
determined in TSGH 9201 cells pretreated with vehicle (DMSO), NF-κB inhibitor Pyrrolidinedithiocarbamate Ammonium (PDTC), or peptides (SN50),
transfected with control siRNA (si-CL), si-p65, or si-p50), and then stimulated with 25 ng/mL resistin for 4 h. SDF-1 mRNA levels were determined
through real-time PCR in TSGH cells and normalized to 18S rRNA. (C) SDF-1-1010-Luc activity were determined in TSGH cells with or without resistin
for 2 h. The SDF-1 promoter p1010-Luc plasmid and several deletion promoter constructs. Right panel: TSGH9201 cells were cotransfected with
5′-deletion constructs and stimulated with 25 ng/mL resistin for 2 h. SDF-1 promoter activity was measured using a luciferase assay normalized to
β-galactosidase activity and was shown to be relative to that of TSGH cells transfected with p1010-Luc (set to 100%). All bar graphs represent folds of
CL cells. *P < 0.05 versus CL (Vehicle control, DMSO and p1010-Luc). (D) TSGH 9201 cells were transfected with control siRNA (si-CL), or a specific siRNA
of si-p65 and si-p50 and then the cells were treated with 25 ng/mL resistin for 6 h. Total cell lysates were extracted, and the proteins of p65, p50 and
β-actin were immunodetected.
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TSGH 9201 cells with resistin resulted in the time-
dependent phosphorylation of p38 MAPK within 2 h.
SDF-1 expression analysis revealed that the resistin in-
duction is mediated by the p38 MAPK-dependent path-
way in TSGH 9201 cells.
TLR4 regulates resistin-induced expression of SDF-1 and
promoter activity
To assess the role of TLR4 in the resistin-induced SDF-1
expression in TSGH 9201 cells, we demonstrated the ef-
fect of the TLR4 antagonist (LPS-RS, complete competi-
tive inhibition) on the resistin-induced SDF-1 expression
and the promoter activity. Pretreatment with LPS-RS
significantly inhibited the expression of SDF-1 mRNA in
TSGH 9201 cells (Figure 3A). To evaluate whether in-
hibition of the SDF-1 expression by the MAPK signaling
pathway occurs at the transcriptional level, we compared
unstimulated cells to those treated with resistin. The
treatment with resistin increased the luciferase activity
8.0 fold compared with the unstimulated cells after
normalization through transfection control. Pretreat-
ment of cells with LPS-RS for 2 h resulted in a marked
1.8- to 2.2-fold inhibition of the resistin-induced SDF-1p1010-Luc promoter activity (Figure 3B). To evaluate
whether the SDF-1 expression by TLR4 involved the
MAPK signaling pathway at the transcriptional level, we
compared control cells to those stimulated with resistin
for 30 min. LPS-RS significantly inhibited the resistin-
induced phosphorylation of p38 MAPK after 2 h
(Figure 3C). Furthermore, TSGH 9201 cells were trans-
fected with the TLR4 siRNA, and the phosphorylation
of p38 MAPK and the SDF-1 expression were then ex-
amined. Figure 3D indicates the effectiveness of TLR4
siRNA on p38 MAPK and SDF-1expression after resis-
tin stimulation.
NF-κB is necessary for resistin induction of human SDF-1
promoter activity
The human SDF-1 gene promoter contains multiple tran-
scription binding sites. To determine the cis-acting
elements in the SDF-1 gene promoter that mediate
resistin-induced SDF-1 transcription, a luciferase assay
was applied using the p1010-Luc plasmid and several
deletion promoter constructs (Figure 4A). To clarify
the binding region of the SDF-1 promoter, we con-
structed and analyzed a series of 5′-deletion mutants.
In TSGH 9201 cells, the −1010/+30 region of SDF-1
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deletion from −1010 to −430 (NF-κB binding sites)
caused luciferase activity to decline to about 30%,
nearly abolishing the activity (Figure 4A).
Further, we assayed whether NF-κB activation was in-
volved in resistin-induced SDF-1 gene expression. TSGH
9201 cells were transfected with p65 or p50 siRNA, or
incubated with specific inhibitors of NF-κB (SN50,
50 μM or PDTC, 50 μM) for 1 h, followed by stimula-
tion with resistin for 4 h. The resistin-induced SDF-1
mRNA expression (Figure 4B) and SDF-1 p1010-Luc
promoter activity (Figure 4C) were significantly inhibited
by SN50, PDTC, or siRNA p50, indicating that NF-κB
p50 is involved in regulating SDF-1 gene induction.
To investigate whether p50 binds the SDF-1 promoter
region in TSGH 9201 cells, we performed quantitative
analysis to determine the binding activity of NF-κB p50
using TF ELISA kits (Figure 5A). The results showed
that treating TSGH 9201 cells with resistin raised the
binding activity of p50 DNA within 2 h. To confirm
these results, ChIP analysis was performed in vitro.
Immunoprecipitated chromosomal DNA with anti-p50
antibody was subjected to PCR using primers designed
to amplify the SDF-1 promoter region (−1010 to −430)Figure 5 NFκB binding activities of the SDF-1 promoter region induce
a TF ELISA assay for 2 h in TSGH 9201 cells . All bar graphs represent folds
was performed for p50 by using p50 antibody. (C) NFκB p50 translocations
50 nM resistin or 0.2% DMSO (as control) for 12 h were fixed, permeabilize
microscopy (left panels) and fluorescence microscopy. Arrows indicate chanharboring the p50 binding sites. NF-κB p50, but not the
control antibody, did indeed bind to the SDF-1 promoter
region (Figure 5B). These data suggest that these se-
quences were indeed p50 binding sites. We used double
labeling of p50 and DAPI to evaluate the effect of resis-
tin in TSGH 9201 cells at 12 h. Representative immuno-
reactivity for phase contrast microscopy, DAPI (blue),
p50 (green), and overlays in the TSGH cells (Figure 5C).
MAPK signaling pathways are involved in resistin-induced
SDF-1 promoter activity
Members of the MAPK family have been implicated in
the regulation of gene expression by resistin [22]. To
evaluate the induction of SDF-1 expression by MAPK
signaling pathways through the transcriptional level, TSGH
9201 cells were incubated with a specific inhibitor of p38
MAPK (SB203580) for 1 h before and during stimulation
with resistin, and the SDF-1 promoter activity and ChIP
were analyzed. The data clearly demonstrated that pretreat-
ment of cells with SB203580 resulted in marked inhibition
of the resistin-induced SDF-1 promoter activity (Figure 6A).
In addition, SB203580 significantly inhibited both resistin-
induced p50 activation (Figure 6B) and NF-κB p50-DNA
binding activity (Figure 6C). We have used TSGH 9201d by resistin induction. (A) NFκB p50 activation was determined by
of control cells (CL), mean ± SEM. *P < 0.05 versus CL. (B) ChIP assay
in nuclei by immunofluorescent staining. TSGH-9201 cells treated with
d, and stained with anti-p50, and then observed by phase contrast
ge and nuclear location.
Figure 6 p38 MAPK and NFκB signaling pathways are involved in resistin-induced SDF-1 promoter activity. (A) SDF-1-1010-Luc activity
was demonstrated in TSGH 9201 cells pretreated with vehicle (DMSO) and SB203580 (SB) individually 1 h, and then stimulated with 25 ng/mL
resistin for 1 h. (B) NFκB p50 activation was determined by TF ELISA assays in TSGH 9201 cells pretreated with vehicle (DMSO) and SB203580 (SB)
individually or in combination for 1 h, and then treated with resistin for 1 h. All bar graphs represent folds of CL in TSGH 9201 cells, mean ± SEM.
*P < 0.05 versus CL. #P < 0.05 vs. vehicle control (DMSO). (C) NFκB p50 binding to SDF-1 promoter in TSGH 9201 cells after 1 h resistin stimulation
was determined by ChIP assay. (D) TSGH 9201 cells were incubated with the p38 inhibitor SB 203580 (SB, 10 μM) for 1 h. Next, the cells were
treated with 25 ng/mL resistin for 12 h. Effect of resistin on the phosphorylation of IκBβ as well as on p50 nuclear translocation. Nuclear and
cytoplasm cell lysate proteins were prepared and analyzed by western blot.
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IκBβ as well as on p50 nuclear translocation. Our data
demonstrate that resistin significantly induced p50 expres-
sion in TSGH 9201 cells via p38 MAPK. Taken together,
these results showed that p38 MARK signaling path-
way are involved in the resistin-induced SDF-1 expres-
sion (Figure 6D).
Discussion
Obesity has been associated with lower rates of survival
in patients with gastric cancer [23]. Adipocytokines such
as TNFα, IL-6, adiponectin, leptin, visfatin, and resistin
are cytokines secreted primarily by visceral adipose tis-
sue and are thought to be involved in the positive correl-
ation between obesity and the increased risk of gastric
cancer [24]. On the other hand, several observers have
suggested that resistin mediates the induction of inflam-
mation in both adipose and non-adipose tissue [25]. The
elevation of resistin and its role in inflammation in the
intestine has resulted in the release of cytokines through
the TLR4/ NF-κB pathway [26-28]. Recent studies have
demonstrated the essential role of the resistin cascade,
and a higher expression of resistin was evident in
intestinal-type gastric carcinomas with tumor differenti-
ation, tumor invasion, and lymph node metastasis [13].
The essential role of resistin, as well as its associationwith gastric cancer, make it a factor of concern as well
as a potential a biomarker for gastric cancer progression
[18]; therefore, it is clinically relevant to study the mech-
anism by which resistin influences tumor cells. In this
study, we evaluated the molecular mechanisms under-
lying the roles of resistin in controlling SDF-1 expression
in gastric cancer cells. SDF-1 was upregulated by resistin
stimulation in TSGH 9201 cells. Resistin-induced ex-
pression of SDF-1 was mediated by the p38 MAPK and
NF-κB pathways, and interaction between resistin and
TLR4 was required for resistin-induced intracellular sig-
naling and SDF-1 expression.
SDF-1 also promotes tumor development by stimulat-
ing angiogenesis and by processing the metastasis of
CXCR4-positive tumor cells to distant organs producing
SDF-1 [27]. Studies have shown that the level of plasma
SDF-1 was higher in the high- incidence cancer group.
In addition, SDF-1 modulates the angiogenic process
directly (by binding to receptors CXCR4 expressed on
endothelial cells) or indirectly (by inducing the secretion
of matrix-metalloproteases or angiogenic factors) [29]. It
has been suggested that SDF-1 is produced by gastric
tumor cells themselves and can act on the tumor cells in
a paracrine or autocrine fashion [30]. In summary, our
study demonstrated that the effect of resistin on TSGH
9201 cells was mediated by the activation of p38 MAPK
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portant role in the expression of SDF-1. TF ELISA and
luciferase assays demonstrated a resistin-induced in-
crease in the NF-κB- and DNA-binding activity. In con-
trast, the inhibition of NF-κB and p38 MAPK activation
in TSGH 9201 cells after treatment with NF-κB and p38
MAPK inhibitors and transfection with specific p50 and
p38 siRNAs prohibited the resistin-induced expression
and secretion of SDF-1.
The promoter region of the SDF-1 gene has several
transcriptional factor binding sites [21]. This study dem-
onstrated the mechanism by which resistin induces SDF-
1 gene expression of gastric cancer cells. The important
findings are as follows: the expression of SDF-1 is medi-
ated by the NF-κB p50 pathway. Construction and ana-
lyses of 5′-deletions in the −1010 to −430 region of the
SDF-1 promoter showed that the activity decreased to
30% and was nearly abolished. ChIP DNA with anti-p50
antibody that was subjected to PCR analysis showed the
SDF-1 promoter region (−1010 to −430) harboring the
NF-κB p50 binding sites. NF-κB proteins are members
of a superfamily of transcription factors whose activities
play a crucial role in cellular activation, proliferation,
and apoptosis, which can be triggered through the
MAPK pathway in gastric cancer cells [31]. During the
early stages of invasion and metastasis of carcinoma
cells, p38 MAPK plays a key role [5,32,33]. In our
present study, we found that the gastric cell line, TSGH
9201, persisted in expressing activated p38 MAPK after
exposure to resistin and high levels of this kinase are
associated with an increased capacity to induce the bind-
ing of NF-κB p50 to the promoter region of SDF-1.
Previous data suggest that regulation of TLR receptors
in gastric carcinogenesis might go beyond H. pylori
infection, and is thought to be associated with tumor
cancers [34]. Resistin has been reported to be signifi-
cantly correlated with stage progression of gastric cancer
[18,35]. We investigated the role of resistin signaling fac-
tors downstream of the p38 MARK and NF-κB activa-
tion sites that lead to SDF-1 transcriptional activation in
TSGH 9201, and the pathophysiological implication of
the role of resistin in gastric cancer should be further
explored.Conclusion
Taken together, our data suggest the mechanism by
which resistin induces SDF-1 expression in gastric can-
cer cells. We found that treatment of gastric cancer
cells with resistin resulted in the activation of signaling
pathways mediated by TLR4. Further studies are re-
quired to explore the potential role of the resistin/
TLR4 axis as an effective therapeutic agent against gas-
tric cancer.Additional file
Additional file 1: Figure S1. Effect of resistin 50 ng/mL on expression
of pro-tumoral CXC chemokines in gastric carcinoma TSGH 9201 at 4 h.
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